Agoracom Blog Home

Posts Tagged ‘Revive Therapeutics’

Novamind $NM.ca Announces Strategic Investment in #Bionomics $BNOEF to Support #PTSD Clinical Trial $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:20 AM on Thursday, February 11th, 2021

Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment

  • Announced that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
  • In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210.
  • BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).

TORONTO, ON / February 11, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.

In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210. BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).

With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in ATAI Life Sciences.

Novamind’s Strategic Investment is included in Bionomics’ latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the “Bionomics Financing”). Novamind will purchase a total of 5,706,800 common shares in the Bionomics Financing, at AU$0.145 per share, a 20% discount to the 30-day volume weighted average price as of February 5th, 2021. Proceeds from the Bionomics Financing will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021.

Bionomics intends to evaluate Cedar Clinical Research’s deep expertise in facilitating Phase I to Phase IV clinical trials for leading pharmaceutical companies, and how it may potentially serve as a research site for Bionomics’ Phase IIb clinical trial examining BNC210 in PTSD patients.

Cedar Clinical Research, led by Novamind’s Chief Medical Officer, Dr. Reid Robison, is currently contracted for seven clinical trials with various sponsors, including leading pharmaceutical companies. Dr. Robison has led over 100 clinical trials in neuropsychiatry, researching a spectrum of psychiatric conditions, including PTSD.

“I’m happy to welcome Novamind as a strategic investor in Bionomics,” said Dr. Errol De Souza, Executive Chairman of Bionomics. “Dr. Robison and the team at Cedar Clinical Research have unique experience related to clinical trials for mental health therapeutics.”

Yaron Conforti, CEO and Director of Novamind, added, “We are pleased to participate in Bionomics’ financing to support the development of its novel drug candidate for the treatment of PTSD. Cedar Clinical Research has unique expertise in PTSD research, and we look forward to the opportunity to contribute to the development of BNC210.”

To learn more about Cedar Clinical Research, please visit cedarclinicalresearch.com.

About Bionomics

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second Phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit bionomics.com.au.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/755165-novamind-announces-strategic-investment-in-bionomics-to-support-ptsd-clinical-trial/messages/2303206#message

Tags: , , , , , , , ,
Posted in Featured, Novamind Inc. | Comments Off on Novamind $NM.ca Announces Strategic Investment in #Bionomics $BNOEF to Support #PTSD Clinical Trial $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Novamind $NM.ca Weekly Roundup $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 3:24 PM on Saturday, January 30th, 2021

A weekly summary of Novamind news and media

The Wall Street Reporter Interviewed Novamind’s CEO, Yaron Conforti

MULTIMEDIA January 27, 2021

Psychedelics and Eating Disorders

OPINION January 23, 2021

Novamind looks to scale mental health clinics and clinical sites with shift in psychedelics policies

MULTIMEDIA January 21, 2021

View all media

Novamind to Present at Canaccord Genuity conference: “New Paradigms & Treatment Approaches in Mental Health”

January 29, 2021

Novamind Reaches Major Milestones for Ketamine and Spravato™ Treatments

January 28, 2021

Novamind Announces Marketing Services Agreements

January 26, 2021

Novamind to Present at Inaugural KCSA Psychedelics Investor Conference

January 25, 2021

Former LifeLabs COO Joins Novamind Leadership Team

January 19, 2021

Novamind Expands Psychedelic Medicine Access in Utah

January 13, 2021

View all press releases

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca

Tags: , , , , , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on Novamind $NM.ca Weekly Roundup $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

#Novamind $NM.ca to Present at Canaccord Genuity Conference: “New Paradigms & Treatment Approaches in #MentalHealth” $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:15 AM on Friday, January 29th, 2021

Conference highlights industry leaders and innovators in the psychedelic therapy space and features Michael Pollan, author of New York Times bestseller, “How to Change Your Mind”

  • Will present at Canaccord Genuity’s “New Paradigms & Treatment Approaches in Mental Health” conference on February 3rd and 4th, 2021.
  • Two-day virtual conference will explore the science, intellectual property, and legality of psychedelic compounds, which are at the forefront of breakthrough medical science.
  • Novamind’s CEO and Director, Yaron Conforti will present on Wednesday February 3rd from 1:30-1:55 PM.

TORONTO, ON / January 29, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a mental health company specialized in psychedelic medicine, today announced that it will present at Canaccord Genuity’s “New Paradigms & Treatment Approaches in Mental Health” conference on February 3rd and 4th, 2021.

The two-day virtual conference will explore the science, intellectual property, and legality of psychedelic compounds, which are at the forefront of breakthrough medical science. Novamind’s CEO and Director, Yaron Conforti will present on Wednesday February 3rd from 1:30-1:55 PM.

Novamind, which has administered over 5,000 ketamine therapy treatments since 2016 and hosted over 20,000 client visits to its clinics in 2020 alone, will share its vision for scaling access to psychedelic medicine and advancing clinical research.

The conference will also feature keynote speaker Michael Pollan, author of the #1 New York Times bestseller “How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence.”

For more information about the conference, please click here.

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/754196-novamind-to-present-at-canaccord-genuity-conference-new-paradigms-treatment-approaches-in-mental-health/messages/2300955#message

Tags: , , , , , , , , , ,
Posted in Novamind Inc. | Comments Off on #Novamind $NM.ca to Present at Canaccord Genuity Conference: “New Paradigms & Treatment Approaches in #MentalHealth” $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Novamind $NM.ca Reaches Major Milestones for #Ketamine and #Spravato(TM) Treatments $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:15 AM on Thursday, January 28th, 2021

  • Announced significant milestones at its Cedar Psychiatry clinics: administering over 5,000 ketamine treatments and over 2,000 Spravato™ treatments.
  • Clients receiving ketamine treatment at Novamind’s Cedar Psychiatry clinics are offered specialized therapy, pre- and post-ketamine-administration (ketamine-assisted psychotherapy).
  • Cedar Psychiatry specializes in evidence-based therapeutic protocols that facilitate the integration of ketamine experiences and optimize treatment outcomes for clients.

TORONTO, ON / January 28, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is proud to announce significant milestones at its Cedar Psychiatry clinics: administering over 5,000 ketamine treatments and over 2,000 Spravato™ treatments.

Launched in 2016, Cedar Psychiatry is a leading provider of innovative, evidence-based mental health therapies in the United States.

Clients receiving ketamine treatment at Novamind’s Cedar Psychiatry clinics are offered specialized therapy, pre- and post-ketamine-administration (ketamine-assisted psychotherapy). Cedar Psychiatry specializes in evidence-based therapeutic protocols that facilitate the integration of ketamine experiences and optimize treatment outcomes for clients.

The number of ketamine treatments administered at Cedar Psychiatry clinics grew 90% from 2019 to 2020. During the same period, total Spravato™ treatments at Cedar Psychiatry clinics have grown over 400%. Spravato™ is a version of ketamine that was approved by the U.S. FDA for treatment-resistant depression (TRD) in March 2019, and for major depressive disorder (MDD) with suicidal ideation or behaviour in August 2020. Clinical research studies that supported FDA approval showed that Spravato™ can effectively benefit people with these conditions, which can be difficult to treat.

“Spravato™ requires specialized infrastructure and processes that can be difficult for small mental health practices to implement, but Cedar Psychiatry has the scale and expertise to effectively manage the challenges of offering these novel medications to our clients,” commented Dr. Reid Robison, Chief Medical Officer and Director of Novamind.

“The need for innovative mental health services has never been greater. This demand is reflected in a sharp increase in visits to our clinics, and the growing adoption by our clients of alternative mental health treatments” added Yaron Conforti, CEO and Director of Novamind.

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/754111-novamind-reaches-major-milestones-for-ketamine-and-spravato-tm-treatments/messages/2300736#message

Tags: , , , , , , , , , , ,
Posted in Novamind Inc. | Comments Off on Novamind $NM.ca Reaches Major Milestones for #Ketamine and #Spravato(TM) Treatments $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Novamind $NM.ca Announces Marketing Services Agreements $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:29 AM on Tuesday, January 26th, 2021
  • Entered into marketing services agreements with Octagon Media Corp.
  • AGORA Internet Relations Corp
  • And a consulting agreement with Venture North Capital Inc.

TORONTO, ON / January 26, 2021 / Novamind Inc., (CSE:NM) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces that is has entered into marketing services agreements with Octagon Media Corp. (“Octagon”) (the “Octagon Marketing Agreement”), AGORA Internet Relations Corp (“AGORA”) (the “AGORA Marketing Agreement”), and a consulting agreement with Venture North Capital Inc. (“VNC”) (the “VNC Agreement”).

In connection with the services provided by Octagon under the Octagon Marketing Agreement, the Company will pay Octagon a cash fee of US$123,000 upon signing, as well as grant Octagon a 12-month option to purchase 100,000 common shares in the capital of the company (the “Shares”) at a price of CAN$1.65 per Share, which will vest fully at signing, and 400,000 warrants to purchase Shares at a price of CAN$1.65 per Share for a period of twelve months from the date of issuance.

The Company also announces that it has entered into a 12-month online marketing services agreement with AGORA Internet Relations Corp., to carry out an online marketing campaign for the purposes of targeting new potential investors that would be specifically interested in the Company’s business model, as well as engaging current shareholders.

In connection with the services provided by AGORA under the AGORA Marketing Agreement, the Company will pay AGORA aggregate consideration of CAN$75,000 plus applicable taxes. The consideration is to be paid via the issuance of Shares. CAN$15,000 of Shares are payable upon commencement of the AGORA Marketing Agreement on January 15, 2021, in consideration of the setup and creation of tools to be used in connection with the services, and an additional CAN$15,000 of Shares are payable every three months thereafter until the end of the AGORA Marketing Agreement’s term.

The number and deemed price of the Shares to be issued will be determined after the date services are provided in each period and are to be calculated using the closing price of the Shares on the Canadian Securities Exchange on each date on which shares are to be issued.

The Company also announces that it has entered into a consulting agreement with Venture North Capital Inc., pursuant to which VNC will provide the Company with investor relations, marketing and communications services for a 6-month term.

In connection with the services provided by VNC under the VNC Agreement, the Company agreed to pay VNC a monthly cash payment of CAN$7,500 per month for six months. The Company has also agreed to issue VNC warrants to purchase 100,000 Shares at a price of CAN$1.65 per Share for a period of twelve months from the date of issuance.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.

Contact Information

Novamind

Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

None of the securities discussed in this news released have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued are anticipated to be issued in reliance upon available exemptions from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

SOURCE: Novamind Inc.

Tags: , , , , , , , , , , , ,
Posted in Novamind Inc. | Comments Off on Novamind $NM.ca Announces Marketing Services Agreements $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Novamind $NM.ca to Present at Inaugural KCSA Psychedelics Investor Conference $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:31 AM on Monday, January 25th, 2021
  • The two-day event will feature presentations by eminent psychedelics companies and industry leaders
  • Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST

TORONTO, ON / January 25, 2021 / Novamind Inc. (CSE:NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, today announced the Company’s participation at the Psychedelics Investor Conference, hosted by KCSA Strategic Communications on Tuesday, January 26th and Wednesday, January 27th from 9:00 AM – 12:30 PM EST.

The two-day event will feature presentations by eminent psychedelics companies and industry leaders. Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST.

“We look forward to connecting with industry leaders and investors to discuss Novamind’s operating model for clinical care and clinical research in psychedelic medicine,” said Conforti.

Read more: https://agoracom.com/ir/Novamind/forums/discussion/topics/753850-novamind-to-present-at-inaugural-kcsa-psychedelics-investor-conference/messages/2300029#message

Tags: , , , , , , , , , , , , ,
Posted in Featured, Novamind Inc. | Comments Off on Novamind $NM.ca to Present at Inaugural KCSA Psychedelics Investor Conference $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca